Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
基本信息
- 批准号:10434864
- 负责人:
- 金额:$ 18.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-13 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS Malignancy ConsortiumAIDS clinical trial groupAIDS related cancerAIDS with Kaposi&aposs sarcomaAdoptedAfricaAfrica South of the SaharaAreaBiologicalBiopsyBleomycinBloodCaringCellsClinicalClinical MarkersClinical TrialsCohort StudiesCollaborationsCollectionCountryData SetDetectionDiseaseDisease MarkerDoxorubicin Hydrochloride LiposomeEligibility DeterminationEnrollmentEuropeFundingGene Expression ProfileGene Expression ProfilingGenetic TranscriptionGenomeGenomicsGoalsHIVHospitalsHumanHuman Herpesvirus 8IL6 geneIncidenceInstitutional Review BoardsInterleukin-10IrisJointsKaposi SarcomaLinkLiposomal DoxorubicinLymphomaLymphoproliferative DisordersMalawiMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of prostateMentorsMolecularNorth CarolinaNucleotidesPaclitaxelPathogenesisPathologyPatientsPersonsPopulationPositioning AttributePrognosisPrognostic FactorPrognostic MarkerPublic SectorPublicationsRandomized Clinical TrialsResearchResearch PersonnelSalivaShippingSiteSouth AfricaStainsTestingTimeTrustUnited States National Institutes of HealthUniversitiesVariantVincristineViralViral Load resultWorkbasebiomarker performancecohortexceptional respondersexosomeexperiencegenome sequencinginnovationlow and middle-income countriesmenmolecular markeroutcome predictionresponseresponse biomarkerscreeningsexstandard of caretreatment guidelinestreatment responsewhole genome
项目摘要
ABSTRACT: PROJECT 2. Clinical and molecular determinants of HIV-associated Kaposi Sarcoma
progression under local standard-of-care therapy in Malawi and South Africa
This application seeks to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC). It responds
to RFA-CA-20-001 and will establish a research center to develop capacity and conduct high-impact research
focused on
HIV-Associated Malignancy in U.S. and Low- and Middle-Income Country. Project 2 - Kaposi
Sarcoma builds on longstanding collaborations between the University of North Carolina at Chapel Hill,
Lighthouse Trust / Kamuzu Central Hospital in Malawi, and Stellenbosch University / Tygerberg Hospital in
South Africa. This project has participation of investigators from all three countries: the US, Malawi and South
Africa. UMSACC will establish and maintain core that support mentoring, administration, pathology and
analyses jointly across three projects. Kaposi sarcoma is by far the most common cancer in people living in
with HIV in Sub Saharan Africa and the US standard of care, liposomal doxorubicin, is not affordable or
available in the public sector. Building on recent randomized clinical trials by the AIDS malignancy Consortium
and the AIDS clinical trials group, we will document the experience with paclitaxel/ cART as new first line
therapy in HIV-KS and seek to develop prognostic biomarkers of the disease, such as KSHV viral load, IL6,
KSHV sequence variants and KSHV transcription.
摘要:项目2。hiv相关卡波西肉瘤的临床和分子决定因素
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dirk P Dittmer其他文献
Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
- DOI:
10.1186/1750-9378-7-s1-o9 - 发表时间:
2012-04-19 - 期刊:
- 影响因子:2.800
- 作者:
Dirk P Dittmer;Blossom Damania;Sang-Hoon Sin;Debasmita Roy - 通讯作者:
Debasmita Roy
The use of high-dose azidothymidine in combination with chemotherapy upfront is an effective treatment approach for gamma-herpes virus-related non-Hodgkin’s lymphomas
- DOI:
10.1186/1750-9378-5-s1-a81 - 发表时间:
2010-10-11 - 期刊:
- 影响因子:2.800
- 作者:
Ulas Darda Bayraktar;Eileen Bernal;Lisa Cabral;William J Harrington;Dirk P Dittmer;Juan Carlos Ramos - 通讯作者:
Juan Carlos Ramos
Dirk P Dittmer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dirk P Dittmer', 18)}}的其他基金
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
- 批准号:
10334549 - 财政年份:2020
- 资助金额:
$ 18.45万 - 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
- 批准号:
10652401 - 财政年份:2020
- 资助金额:
$ 18.45万 - 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
- 批准号:
10084558 - 财政年份:2020
- 资助金额:
$ 18.45万 - 项目类别:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
- 批准号:
10579826 - 财政年份:2020
- 资助金额:
$ 18.45万 - 项目类别:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6:卡波西肉瘤转基因小鼠模型
- 批准号:
10115683 - 财政年份:2020
- 资助金额:
$ 18.45万 - 项目类别:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
项目 2:马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素
- 批准号:
10238161 - 财政年份:2020
- 资助金额:
$ 18.45万 - 项目类别:
Planning for a National Non-Communicable Disease Center of Research Excellence
规划国家非传染性疾病卓越研究中心
- 批准号:
9337384 - 财政年份:2016
- 资助金额:
$ 18.45万 - 项目类别:
Planning for a National Non-Communicable Disease Center of Research Excellence
规划国家非传染性疾病卓越研究中心
- 批准号:
9193832 - 财政年份:2016
- 资助金额:
$ 18.45万 - 项目类别:
Origin and Lineage of Differentiation of Kaposi's Sarcoma
卡波西肉瘤的起源和分化谱系
- 批准号:
8839925 - 财政年份:2015
- 资助金额:
$ 18.45万 - 项目类别:
HIV and substances of abuse influence exosomes and endothelial cell function
HIV 和滥用物质影响外泌体和内皮细胞功能
- 批准号:
9304176 - 财政年份:2015
- 资助金额:
$ 18.45万 - 项目类别:
相似海外基金
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
- 批准号:
7718385 - 财政年份:2008
- 资助金额:
$ 18.45万 - 项目类别:
PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)
儿科晚期结果(艾滋病临床试验组
- 批准号:
7603425 - 财政年份:2007
- 资助金额:
$ 18.45万 - 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
- 批准号:
7605681 - 财政年份:2007
- 资助金额:
$ 18.45万 - 项目类别:
PACTG(PEDIATRIC AIDS CLINICAL TRIAL GROUP) 1058 : PHARMACOKINETIC STUDIES
PACTG(儿科艾滋病临床试验组)1058:药代动力学研究
- 批准号:
7603580 - 财政年份:2007
- 资助金额:
$ 18.45万 - 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
- 批准号:
7378240 - 财政年份:2006
- 资助金额:
$ 18.45万 - 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -
成人艾滋病临床试验组纵向连锁随机试验 (ALLRT) -
- 批准号:
7606380 - 财政年份:2006
- 资助金额:
$ 18.45万 - 项目类别: